Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule novel pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases, and cancer. The Company has late-stage compounds in development and continues to discover additional compounds and to progress them to meet the unmet medical needs of patients and physicians.
Website: biocryst.com



Growth: Good revenue growth rate 41.9%, there is slowdown compared to average historical growth rates 49.0%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +12.2%. On average the margin is improving steadily. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 102.2% higher than minimum and 43.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.5x by EV / Sales multiple , the company can be 19.1% undervalued

Key Financials (Download financials)

Ticker: BCRX
Share price, USD:  (-2.9%)8.35
year average price 8.30  


year start price 7.63 2024-08-09

min close price 6.41 2025-04-10

max close price 11.19 2025-06-03

current price 8.35 2025-08-08
Common stocks: 207 381 000

Dividend Yield:  0.0%
FCF Yield LTM: 0.2%
EV / LTM EBITDA: 31.0x
EV / EBITDA annualized: 8.4x
Last revenue growth (y/y):  +41.9%
Last growth of EBITDA (y/y):  > +200.0%
Historical revenue growth:  +49.0%
Historical growth of EBITDA:  +70.4%
EV / Sales: 3.8x
Margin (EBITDA LTM / Revenue): 12.2%
Fundamental value created in LTM:
Market Cap ($m): 1 732
Net Debt ($m): -26
EV (Enterprise Value): 1 706
Price to Book: -3.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-08-04seekingalpha.com

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript

2025-08-04zacks.com

BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates

2025-07-31zacks.com

BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock

2025-07-28zacks.com

BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth

2025-07-07zacks.com

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?

2025-05-26zacks.com

Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade

2025-05-09zacks.com

New Strong Buy Stocks for May 9th

2025-05-08zacks.com

Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?

2025-05-05benzinga.com

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

2025-04-10zacks.com

How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BCRX BCRX BCRX BCRX BCRX BCRX BCRX BCRX BCRX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 882 796 882 796 882 796 882 796 882 796 882 796 882 796 882 796 882 796
fillingDate 2024-11-05 2024-08-06 2024-05-07 2024-02-27 2023-11-08 2023-08-07 2023-05-08 2023-02-27 2022-11-04
acceptedDate 2024-11-05 17:19:10 2024-08-06 16:04:28 2024-05-07 16:02:30 2024-02-27 16:07:19 2023-11-08 16:12:06 2023-08-07 16:55:43 2023-05-08 16:37:44 2023-02-27 16:38:47 2022-11-04 16:18:55
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 117M 109M 93M 93M 87M 82M 69M 80M 76M
costOfRevenue 3M 2M 1M 2M 1M 950 000 938 000 2M 4M
grossProfit 114M 107M 91M 91M 86M 82M 68M 77M 72M
grossProfitRatio 0.972 0.981 0.986 0.978 0.987 0.988 0.986 0.969 0.952
researchAndDevelopmentExpenses 41M 37M 46M 70M 47M 51M 48M 73M 53M
generalAndAdministrativeExpenses 0 0 0 50M 0 48M 0 0 0
sellingAndMarketingExpenses 0 0 0 14M 0 3M 0 0 0
sellingGeneralAndAdministrativeExpenses 65M 61M 59M 64M 51M 51M 48M 50M 37M
otherExpenses 0 35 000 127 000 180 000 37 000 56 000 7000 260M 0
operatingExpenses 106M 99M 106M 134M 98M 102M 96M 123M 90M
costAndExpenses 109M 101M 107M 136M 99M 103M 97M 126M 93M
interestIncome 4M 4M 4M 4M 4M 4M 3M 3M 2M
interestExpense 25M 25M 25M 25M 27M 29M 27M 26M 25M
depreciationAndAmortization 311 000 320 000 306 000 43 812 4M 4M 3M 3M 2M
ebitda 12M 9M -10M -42M -8M -17M -25M -44M -16M
ebitdaratio 0.1 0.083 -0.109 -0.452 -0.089 -0.206 -0.364 -0.548 -0.207
operatingIncome 8M 9M -14M -43M -12M -21M -28M -46M -17M
operatingIncomeRatio 0.066 0.08 -0.155 -0.457 -0.137 -0.251 -0.413 -0.582 -0.23
totalOtherIncomeExpensesNet -21M -21M -21M -20M -737 000 -29M -24M -25M -24M
incomeBeforeTax -13M -13M -35M -63M -36M -75M -53M -71M -41M
incomeBeforeTaxRatio -0.115 -0.114 -0.377 -0.676 -0.413 -0.904 -0.766 -0.898 -0.541
incomeTaxExpense 586 000 172 000 365 000 -1M 330 000 740 000 671 000 76 000 2M
netIncome -14M -13M -35M -62M -36M -75M -53M -72M -43M
netIncomeRatio -0.12 -0.116 -0.381 -0.661 -0.417 -0.913 -0.775 -0.899 -0.561
eps -0.068 -0.061 -0.17 -0.31 -0.19 -0.4 -0.28 -0.38 -0.23
epsdiluted -0.068 -0.061 -0.17 -0.31 -0.19 -0.4 -0.28 -0.38 -0.23
weightedAverageShsOut 207M 206M 206M 201M 190M 189M 189M 187M 186M
weightedAverageShsOutDil 207M 206M 206M 201M 190M 189M 189M 187M 186M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BCRX BCRX BCRX BCRX BCRX BCRX BCRX BCRX BCRX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 882 796 882 796 882 796 882 796 882 796 882 796 882 796 882 796 882 796
fillingDate 2024-11-05 2024-08-06 2024-05-07 2024-02-27 2023-11-08 2023-08-07 2023-05-08 2023-02-27 2022-11-04
acceptedDate 2024-11-05 17:19:10 2024-08-06 16:04:28 2024-05-07 16:02:30 2024-02-27 16:07:19 2023-11-08 16:12:06 2023-08-07 16:55:43 2023-05-08 16:37:44 2023-02-27 16:38:47 2022-11-04 16:18:55
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 97M 80M 84M 112M 151M 146M 155M 305M 247M
shortTermInvestments 233M 194M 252M 278M 247M 268M 243M 120M 180M
cashAndShortTermInvestments 330M 274M 337M 391M 398M 414M 402M 442M 461M
netReceivables 72M 69M 61M 57M -352M -365M 49M 51M 43M
inventory 8M 4M 30M 29M 30M 27M 27M 28M 27M
otherCurrentAssets 17M 18M 18M 20M 322M 338M 308M 13M 11M
totalCurrentAssets 427M 363M 447M 496M 398M 414M 491M 517M 509M
propertyPlantEquipmentNet 23M 20M 8M 21M 9M 8M 8M 15M 15M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 19M 64M 0 0 0 3M 3M 18M 34M
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 22M 25M 13M 0 11M 7M 7M 0 0
totalNonCurrentAssets 64M 109M 21M 21M 20M 19M 19M 34M 50M
otherAssets 0 1 0 0 -1 104M 97M 0 0 0
totalAssets 491M 472M 468M 517M -686M 530M 510M 550M 559M
accountPayables 13M 8M 12M 21M 11M 14M 6M 14M 9M
shortTermDebt 3M 32M 3M 26M 2M 3M 2M 2M 2M
taxPayables 0 0 0 0 0 0 0 410 000 0
deferredRevenue 0 0 79M 0 522 000 2M 1M 1M 2M
otherCurrentLiabilities 137M 90M 26M 103M 77M 75M 75M 88M 69M
totalCurrentLiabilities 154M 129M 120M 150M 91M 93M 85M 106M 82M
longTermDebt 806M 819M 824M 811M 10M 6M 6M 739M 720M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 11M 0 0 0 0 707M
totalNonCurrentLiabilities 806M 819M 824M 823M 10M 6M 6M 739M 720M
otherLiabilities 0 0 0 0 833M 819M 747M 0 0
capitalLeaseObligations 13M 13M 14M 11M 10M 6M 6M 8M 8M
totalLiabilities 960M 948M 944M 972M 934M 919M 838M 845M 801M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 2M 2M 2M 2M 2M 2M 2M 2M 2M
retainedEarnings -1 743M -1 729M -1 717M -1 681M -1 619M -1 583M -1 508M -1 455M -1 383M
accumulatedOtherComprehensiveIncomeLoss 2M 557 000 771 000 1M 800 000 690 000 585 000 26 000 -98 000
othertotalStockholdersEquity 1 270M 1 251M 1 238M 1 222M -3M -3M -2M -2M -2M
totalStockholdersEquity -469M -476M -476M -456M -1 619M -1 583M -1 508M -1 455M -1 383M
totalEquity -469M -476M -476M -456M -1 619M -1 583M -1 508M -1 455M -1 383M
totalLiabilitiesAndStockholdersEquity 491M 472M 468M 517M -686M -665M -670M -610M -582M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 491M 472M 468M 517M -686M -665M -670M -610M -582M
totalInvestments 253M 258M 252M 278M 247M 3M 3M 138M 214M
totalDebt 809M 851M 827M 849M 10M 6M 6M 741M 722M
netDebt 712M 770M 743M 736M -141M -140M -149M 437M 475M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BCRX BCRX BCRX BCRX BCRX BCRX BCRX BCRX BCRX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 882 796 882 796 882 796 882 796 882 796 882 796 882 796 882 796 882 796
fillingDate 2024-11-05 2024-08-06 2024-05-07 2024-02-27 2023-11-08 2023-08-07 2023-05-08 2023-02-27 2022-11-04
acceptedDate 2024-11-05 17:19:10 2024-08-06 16:04:28 2024-05-07 16:02:30 2024-02-27 16:07:19 2023-11-08 16:12:06 2023-08-07 16:55:43 2023-05-08 16:37:44 2023-02-27 16:38:47 2022-11-04 16:18:55
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -14M -13M -35M -62M -36M -75M -53M -72M -43M
depreciationAndAmortization -8M 320 000 306 000 423 000 420 000 407 000 405 000 396 000 389 000
deferredIncomeTax 0 0 0 475 000 -13M 26M 0 0 0
stockBasedCompensation 17M 13M 14M 16M 12M 13M 14M 15M 10M
changeInWorkingCapital 67M -18M -49M 18M -16M -7M -28M -12M -18M
accountsReceivables -3M -8M -4M -3M 4M -9M 2M -9M 0
inventory 2M 739 000 -1M 907 000 -3M 898 000 131 000 -1M -4M
accountsPayables -3M -13M -45M 20M -15M -188 000 -27M 5M -19M
otherWorkingCapital 71M 2M 1M 291 000 -1M 2M -3M -7M 5M
otherNonCashItems -53M 50M 19M 17M 32M 24M 19M 44M 18M
netCashProvidedByOperatingActivities 8M -2M -54M -9M -20M -19M -48M -24M -32M
investmentsInPropertyPlantAndEquipment 390 000 -155 000 -235 000 -554 000 -987 000 -467 000 -160 000 -526 000 -175 000
acquisitionsNet 0 0 0 5M -24M 19M 160 000 0 0
purchasesOfInvestments -27M -112M -88M -157M -124M -85M -149M 0 -105M
salesMaturitiesOfInvestments 35M 110M 117M 129M 148M 66M 42M 78M 36M
otherInvestingActivites -449 000 -2M -235 000 1 24M -19M -160 000 0 0
netCashUsedForInvestingActivites 8M -2M 29M -28M 23M -19M -107M 77M -70M
debtRepayment -556 000 0 -390 000 -1M -262 000 -27M 0 0 0
commonStockIssued 6000 12 000 11 000 164 000 1M 2M 5M 7M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 2M -2M -2M -2M -262 000 55M 0 -3M 76M
netCashUsedProvidedByFinancingActivities 1M -2M -1M -3M 1M 29M 5M 4M 76M
effectOfForexChangesOnCash 851 000 -143 000 -340 000 522 000 253 000 -317 000 -96 000 331 000 -14 000
netChangeInCash 19M -6M -26M -40M 5M -9M -150M 58M -26M
cashAtEndOfPeriod 99M 80M 86M 112M 152M 148M 157M 306M 248M
cashAtBeginningOfPeriod 80M 86M 112M 152M 148M 157M 306M 248M 274M
operatingCashFlow 8M -2M -54M -9M -20M -19M -48M -24M -32M
capitalExpenditure -59 000 -155 000 -235 000 -554 000 -987 000 -467 000 -160 000 -526 000 -175 000
freeCashFlow 8M -2M -54M -9M -21M -19M -48M -24M -33M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-04 ET (fiscal 2024 q3)
2024 q2
2024-08-05 ET (fiscal 2024 q2)
2024 q1
2024-05-06 ET (fiscal 2024 q1)
2023 q4
2024-02-26 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-21 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-11-05 12:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-11-04 12:00 ET
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-10-24 12:00 ET
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)
2024-10-21 11:00 ET
BioCryst to Report Third Quarter 2024 Financial Results on November 4
2024-10-14 11:00 ET
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)
2024-10-10 11:00 ET
BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
2024-10-03 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-10-02 11:00 ET
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
2024-09-30 11:00 ET
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile
2024-09-06 06:00 ET
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
2024-09-05 11:00 ET
BioCryst Appoints Dr. Donald Fong Chief Medical Officer
2024-09-04 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-22 11:00 ET
BioCryst to Present at Upcoming Investor Conferences
2024-08-05 11:00 ET
BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
2024-08-02 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-07-22 11:00 ET
BioCryst to Report Second Quarter 2024 Financial Results on August 5
2024-07-09 11:00 ET
ORLADEYO® (berotralstat) Approved in Peru
2024-07-02 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-06-04 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-06-02 08:00 ET
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
2024-05-14 11:00 ET
BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
2024-05-13 11:00 ET
ORLADEYO® (berotralstat) Approved in Mexico
2024-05-09 11:00 ET
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)
2024-05-07 11:00 ET
BioCryst to Present at Upcoming Investor Conferences
2024-05-06 11:00 ET
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
2024-05-03 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-22 11:00 ET
BioCryst to Report First Quarter 2024 Financial Results on May 6
2024-04-17 08:30 ET
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
2024-04-03 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-25 20:01 ET
BioCryst to Present at Upcoming Investor Conferences
2024-03-05 12:01 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-26 12:00 ET
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
2024-02-23 12:00 ET
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment
2024-02-21 21:01 ET
BioCryst to Present at Upcoming Investor Conferences
2024-02-19 12:54 ET
BioCryst Launches ORLADEYO® (berotralstat) in Italy
2024-02-12 12:00 ET
BioCryst to Report Fourth Quarter 2023 Financial Results on February 26
2024-02-05 12:00 ET
BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
2024-02-02 12:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-05 21:01 ET
BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability
2024-01-03 21:01 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-03 12:00 ET
BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-19 12:00 ET
BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)
2023-12-05 21:01 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-29 12:00 ET
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina
2023-11-21 21:01 ET
BioCryst to Present at Upcoming Investor Conferences
2023-11-21 12:00 ET
BioCryst Launches ORLADEYO® (berotralstat) in Spain
2023-11-10 12:00 ET
BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)
2023-11-06 21:01 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-03 16:03 ET
BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months
2023-11-02 11:00 ET
BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-10-27 11:00 ET
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
2023-10-26 11:00 ET
BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013
2023-10-20 11:00 ET
BioCryst to Host R&D Day on November 3
2023-10-19 11:00 ET
BioCryst to Report Third Quarter 2023 Financial Results on November 2
2023-10-04 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-18 11:00 ET
INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec
2023-09-05 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-23 20:01 ET
BioCryst to Present at Upcoming Investor Conferences
2023-08-04 20:01 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-03 11:00 ET
BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-07-20 11:00 ET
BioCryst to Report Second Quarter 2023 Financial Results on August 3
2023-07-19 11:00 ET
BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey
2023-07-17 11:00 ET
BioCryst to Participate in the 2023 US HAEA National Summit
2023-07-06 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-06 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-01 11:00 ET
BioCryst to Present at Upcoming Investor Conference
2023-05-31 11:02 ET
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress
2023-05-22 11:00 ET
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile
2023-05-04 20:01 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-03 11:00 ET
BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update
2023-04-27 11:00 ET
BioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat)
2023-04-19 11:00 ET
BioCryst to Report First Quarter 2023 Financial Results on May 3
2023-04-18 11:00 ET
BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon
2023-04-12 11:00 ET
BioCryst to Present at Upcoming Investor Conferences
2023-04-04 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-31 11:00 ET
BioCryst Appoints Dr. Nancy Hutson as Chair of the Board
2023-03-29 20:01 ET
BioCryst Celebrates Bob Ingram’s Contributions to the Company’s Success
2023-03-08 20:00 ET
CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada
2023-03-02 12:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-02-24 12:00 ET
BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)
2023-02-22 12:00 ET
BioCryst to Present at Upcoming Investor Conferences
2023-02-21 12:00 ET
BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones
2023-02-07 12:00 ET
BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
2023-02-06 12:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-02-03 12:00 ET
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
2023-01-26 12:00 ET
BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema
2023-01-23 12:00 ET
BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe
2023-01-09 12:05 ET
BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance
2023-01-09 12:00 ET
BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases
2023-01-05 12:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-01-04 12:00 ET
BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference
2022-12-15 12:00 ET
BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013
2022-12-05 21:01 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-12-05 12:00 ET
BioCryst to Present at JMP Securities Hematology & Oncology Summit
2022-11-28 12:00 ET
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health
2022-11-10 13:00 ET
BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy
2022-11-09 12:00 ET
BioCryst to Present at Upcoming Investor Conferences
2022-11-04 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-01 11:00 ET
BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones
2022-10-24 11:00 ET
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
2022-10-18 11:00 ET
BioCryst to Report Third Quarter 2022 Financial Results on November 1
2022-10-04 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-09-14 20:01 ET
BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer
2022-09-06 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-08-31 20:01 ET
BioCryst to Present at Upcoming Investor Conferences
2022-08-31 11:00 ET
FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva
2022-08-26 11:00 ET
BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients
2022-08-25 11:00 ET
U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness
2022-08-18 11:00 ET
BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia
2022-08-04 11:00 ET
BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones
2022-08-04 10:58 ET
BioCryst Resumes Enrollment in BCX9930 Clinical Program
2022-07-21 11:00 ET
BioCryst to Report Second Quarter 2022 Financial Results on August 4
2022-07-15 11:00 ET
BioCryst to Present at Upcoming Investor Conference
2022-07-01 11:00 ET
BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)
2022-06-22 11:00 ET
BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022
2022-06-09 11:00 ET
BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America
2022-06-08 11:00 ET
FDA Grants Fast Track Designation for BioCryst’s ALK-2 Inhibitor, BCX9250
2022-06-07 13:00 ET
BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic
2022-06-06 11:00 ET
BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks
2022-06-01 11:00 ET
BioCryst to Present at Upcoming Investor Conferences
2022-05-06 11:00 ET
BioCryst to Present at Upcoming Investor Conferences
2022-05-05 11:00 ET
BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
2022-05-04 20:15 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-04-27 11:00 ET
European Medicines Agency Grants PRIME Designation to BioCryst’s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva
2022-04-21 11:00 ET
BioCryst to Report First Quarter 2022 Financial Results on May 5
2022-04-11 12:30 ET
BioCryst to Present at Upcoming Investor Conference
2022-04-08 13:15 ET
BioCryst Pauses Enrollment in BCX9930 Clinical Trials
2022-04-05 11:15 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-03-03 12:00 ET
BioCryst to Present at Upcoming Investor Conferences
2022-03-02 12:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-02-24 12:00 ET
BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)
2022-02-23 12:00 ET
BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones
2022-02-22 12:00 ET
BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases
2022-02-09 12:00 ET
BioCryst to Report Fourth Quarter 2021 Financial Results on February 23
2022-02-08 12:00 ET
BioCryst Appoints Machelle Sanders to Board of Directors
2022-02-03 12:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-02-01 14:25 ET
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting
2022-01-10 12:00 ET
BioCryst Announces Preliminary Full Year 2021 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales Guidance
2022-01-07 14:25 ET
BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
2022-01-04 21:15 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-01-04 12:00 ET
BioCryst to Present at 40th Annual J.P. Morgan Healthcare Conference
2021-12-03 12:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-11-29 13:30 ET
BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
2021-11-22 12:10 ET
Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals
2021-11-22 12:00 ET
BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
2021-11-12 12:00 ET
BioCryst to Present at Upcoming Investor Conferences
2021-11-05 11:00 ET
BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat)
2021-11-03 11:00 ET
BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones
2021-11-02 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-11-01 11:00 ET
BioCryst Appoints Jinky Ang Rosselli Chief Data and Insights Officer
2021-10-26 11:00 ET
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
2021-10-20 11:00 ET
BioCryst to Report Third Quarter 2021 Financial Results on November 3
2021-10-04 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-09-21 11:00 ET
BioCryst to Present at 2021 Cantor Virtual Healthcare Conference
2021-09-20 11:00 ET
BioCryst Appoints Dr. Amy McKee to Board of Directors
2021-09-16 00:20 ET
NICE Recommends BioCryst’s ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UK
2021-09-09 11:00 ET
BioCryst Announces Approval of ORLADEYO® (berotralstat) in United Arab Emirates
2021-09-03 11:00 ET
BioCryst to Present at Upcoming Investor Conferences
2021-09-02 20:01 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-09-01 11:00 ET
U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to Strategic National Stockpile
2021-08-26 11:00 ET
BioCryst Appoints Dr. Steven Galson to Board of Directors
2021-08-25 20:01 ET
BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic
2021-08-10 22:55 ET
BioCryst Withdraws Public Offering
2021-08-09 20:01 ET
BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants
2021-08-05 11:00 ET
BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones
2021-08-03 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-07-28 11:00 ET
BioCryst Appoints Vincent Milano to Board of Directors
2021-07-22 11:00 ET
BioCryst to Report Second Quarter 2021 Financial Results on August 5
2021-07-15 11:00 ET
BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH
2021-07-10 14:00 ET
BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline
2021-07-01 20:15 ET
ORLADEYO™ (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
2021-06-16 11:00 ET
BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Israeli Ministry of Health
2021-06-03 11:00 ET
BioCryst Launches ORLADEYO™ (berotralstat) in Germany
2021-05-26 11:00 ET
BioCryst to Present at Upcoming Investor Conferences
2021-05-12 13:25 ET
BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
2021-05-06 11:00 ET
BioCryst Reports First Quarter 2021 Financial Results and Upcoming Key Milestones
2021-05-05 11:00 ET
BioCryst to Present at Upcoming Investor Conferences
2021-04-30 13:21 ET
BioCryst Receives European Commission Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
2021-04-22 11:00 ET
BioCryst to Report First Quarter 2021 Financial Results on May 6
2021-04-14 12:15 ET
BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema
2021-04-07 11:00 ET
BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
2021-03-22 12:00 ET
BioCryst’s Oral Factor D Inhibitor, BCX9930, Advancing to Pivotal Trials in PNH Following Successful Proof of Concept Trial
2021-03-19 11:00 ET
BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer
2021-03-15 11:00 ET
BioCryst to Host Virtual R&D Day on March 22, 2021
2021-03-11 13:30 ET
Early Access to BioCryst’s Berotralstat Granted for HAE Patients in France
2021-03-02 12:00 ET
BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
2021-02-25 21:15 ET
BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
2021-02-25 12:00 ET
BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones
2021-02-18 12:00 ET
BioCryst to Present at Upcoming Investor Conferences
2021-02-11 12:00 ET
BioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February 25
2021-02-09 12:15 ET
BioCryst to Present Data at 2021 American Academy of Allergy, Asthma & Immunology Annual Meeting
2021-02-03 12:00 ET
BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older
2021-02-02 12:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-01-22 12:00 ET
BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema
2021-01-07 12:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-01-06 12:00 ET
BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference
2020-12-22 12:00 ET
BioCryst Provides Update on Galidesivir Program
2020-12-21 12:00 ET
BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva
2020-12-16 12:00 ET
BioCryst Announces U.S. Availability of ORLADEYO™ (berotralstat) for the Treatment of Hereditary Angioedema
2020-12-11 12:00 ET
BioCryst to Present at JMP Securities Hematology Summit
2020-12-07 13:45 ET
Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCryst Pharmaceuticals
2020-12-07 13:40 ET
BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management
2020-12-06 15:00 ET
BioCryst’s Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement
2020-12-04 01:45 ET
BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
2020-12-01 21:15 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-11-30 12:00 ET
Allergy Publishes Results from BioCryst’s APeX-J Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE Attacks
2020-11-20 12:00 ET
BioCryst to Present at Upcoming Virtual Investment Conferences
2020-11-13 12:02 ET
BioCryst Presents Data Showing Sustained Attack Rate Reductions, Improved Patient Satisfaction and Quality of Life for HAE Patients Taking Berotralstat in APeX-2 Trial
2020-11-13 12:00 ET
BioCryst Presents New Data Highlighting Burden of Therapy with Current Injectable Prophylaxis Medication for HAE
2020-11-12 12:00 ET
BioCryst to Present Data at the 2020 ASH Annual Meeting
2020-11-05 12:00 ET
BioCryst Reports Third Quarter 2020 Financial Results and Upcoming Key Milestones
2020-11-02 21:15 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-10-30 12:15 ET
MHRA Grants HAE Patients Early Access to BioCryst’s Berotralstat in United Kingdom
2020-10-28 11:00 ET
Biocryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
2020-10-22 20:15 ET
BioCryst to Report Third Quarter 2020 Financial Results on November 5
2020-10-22 11:00 ET
Journal of Allergy and Clinical Immunology Publishes Results from BioCryst’s APeX-2 Pivotal Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE Attacks
2020-10-05 20:15 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-09-30 11:00 ET
BioCryst’s Oral Factor D Inhibitor, BCX9930, Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-naïve PNH Patients
2020-09-08 11:00 ET
BioCryst to Present at 22nd Annual H.C. Wainwright Global Investment Conference
2020-09-03 20:15 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-09-03 11:00 ET
U.S. Government Exercises Option To Purchase Additional RAPIVAB® from BioCryst for Delivery to Strategic National Stockpile
2020-08-31 13:29 ET
NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir
2020-08-31 11:00 ET
FDA Grants Orphan Drug Designation for BCX9930 in PNH
2020-08-06 11:00 ET
BioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key Milestones
2020-08-04 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-08-03 11:00 ET
FDA Grants Fast Track Designation for BCX9930 in PNH
2020-07-23 11:00 ET
BioCryst to Report Second Quarter 2020 Financial Results on August 6
2020-07-02 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-06-10 18:00 ET
Galidesivir Stops Zika Viral Replication in Primate Model
2020-06-09 20:15 ET
BioCryst Announces Berotralstat Expanded Access Program for Patients with Hereditary Angioedema in United States
2020-06-06 07:01 ET
Hereditary Angioedema Patients Report Breakthrough Attacks on Current Injectable/Infused Prophylaxis Medication
2020-06-06 07:00 ET
Long-term (48-week) Data Show Treatment with Berotralstat Provides Robust and Durable Reductions in HAE Attacks and Improvements in Quality of Life Scores
2020-06-02 11:15 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-06-01 20:01 ET
BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock and Pre-Funded Warrants
2020-05-28 20:15 ET
BioCryst to Present at Jefferies Virtual Healthcare Conference
2020-05-28 03:35 ET
BioCryst Prices Public Offering of Common Stock and Pre-Funded Warrants
2020-05-27 20:01 ET
BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants
2020-05-26 11:00 ET
BioCryst to Present New Berotralstat Data at European Academy of Allergy and Clinical Immunology Digital Congress
2020-05-15 11:00 ET
BioCryst Celebrates HAE Patients with HAE Global Walk
2020-05-07 11:00 ET
BioCryst to Present at Upcoming Investor Conferences
2020-05-06 11:00 ET
BioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones
2020-05-05 11:00 ET
New Composition of Matter Patent Allowance Extends Protection for Berotralstat in U.S. Market by Four Years to 2039
2020-05-04 20:15 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-04-22 11:00 ET
BioCryst to Report First Quarter 2020 Financial Results on May 6
2020-04-09 20:45 ET
BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19
2020-04-08 11:00 ET
BioCryst to Present at 19th Annual Needham Healthcare Conference
2020-04-03 11:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-04-02 11:00 ET
BioCryst Appoints Anthony Doyle Chief Financial Officer
2020-03-30 11:00 ET
European Medicines Agency Validates Marketing Authorization Application for Oral, Once-Daily Berotralstat (BCX7353) to Prevent HAE Attacks
2020-03-16 11:10 ET
BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE ON-DEMAND MEDICINE IN HAE PATIENTS IN APEX-2
2020-03-05 12:05 ET
BioCryst Reports Fourth Quarter and Full Year 2019 Financial Results and Upcoming Key Milestones
2020-03-05 12:00 ET
BioCryst Begins Proof of Concept Trial in PNH Patients With Oral Factor D Inhibitor, BCX9930
2020-03-03 12:00 ET
BioCryst to Present at Barclays Global Healthcare Conference
2020-03-02 21:15 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2020-02-27 12:00 ET
BioCryst to Present New Data at American Academy of Allergy, Asthma & Immunology Annual Meeting
2020-02-25 12:00 ET
BioCryst Appoints Alan G. Levin to Board of Directors
2020-02-20 12:00 ET
BioCryst to Report Fourth Quarter and Full Year 2019 Financial Results on March 5
2020-02-18 12:00 ET
FDA Accepts BioCryst’s NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks
2020-02-06 12:00 ET
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-02-03 12:00 ET
BioCryst Submits Japanese New Drug Application for Oral, Once Daily Berotralstat
2020-01-15 12:00 ET
BioCryst Strengthens Commercial Rare Disease Leadership
2020-01-12 21:00 ET
BioCryst to Provide Berotralstat and BCX9930 Program Updates at 38th Annual J.P. Morgan Healthcare Conference
2020-01-06 12:00 ET
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
2020-01-03 12:00 ET
BioCryst to Present at 38th Annual J.P. Morgan Healthcare Conference
2019-12-11 12:00 ET
BioCryst Submits New Drug Application for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks
2019-12-04 12:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-11-18 21:01 ET
BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
2019-11-14 21:01 ET
BioCryst to Present at Upcoming Investor Conferences
2019-11-14 00:10 ET
BioCryst Prices Public Offering of Common Stock
2019-11-12 21:01 ET
BioCryst Commences Public Offering of Common Stock
2019-11-07 12:00 ET
Biocryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
2019-11-06 12:00 ET
BioCryst Reports Third Quarter 2019 Financial Results and Upcoming Key Milestones
2019-11-06 11:55 ET
New Clinical Trial Results and Market Research Support Significant Commercial Opportunity for Oral, Once Daily BCX7353 in HAE
2019-11-05 06:05 ET
BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks       
2019-11-04 12:00 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-11-01 11:00 ET
BioCryst Begins Phase 1 Trial With BCX9250, an Oral ALK-2 Inhibitor, for Treatment of Fibrodysplasia Ossificans Progressiva
2019-10-29 11:00 ET
BioCryst to Provide Commercial Update and Report Third Quarter 2019 Financial Results on November 6
2019-10-28 10:59 ET
BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients
2019-10-03 11:00 ET
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2019-09-26 11:15 ET
U.S. Government Exercises Option for Additonal Rapivab® for Strategic National Stockpile
2019-09-24 20:15 ET
BioCryst Pharmaceuticals to Present at Cantor Global Healthcare Conference
2019-09-23 11:00 ET
BioCryst Appoints Helen Thackray, M.D., to Board of Directors
2019-03-04 12:02 ET
BioCryst Reports Fourth Quarter and Full Year 2018 Financial Results
2019-03-04 12:00 ET
BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development
2019-02-28 12:00 ET
BioCryst to Present at Barclays Global Healthcare Conference

SEC forms

Show financial reports only

SEC form 8
2025-08-04 11:12 ET
BioCryst Pharmaceuticals reported for 2025 q2
SEC form 8
2025-08-04 11:12 ET
BioCryst Pharmaceuticals published news for 2025 q2
SEC form 8
2025-06-30 11:37 ET
BioCryst Pharmaceuticals published news for 2025 q1
SEC form 8
2025-06-30 11:37 ET
BioCryst Pharmaceuticals published news for 2025 q1
SEC form 8
2025-06-27 11:10 ET
BioCryst Pharmaceuticals published news for 2025 q1
SEC form 8
2025-06-27 11:10 ET
BioCryst Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-14 11:16 ET
BioCryst Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-14 11:16 ET
BioCryst Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-06 20:03 ET
BioCryst Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-06 00:00 ET
BioCryst Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-05 00:00 ET
BioCryst Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-05 00:00 ET
BioCryst Pharmaceuticals reported for 2025 q1
SEC form 10
2025-02-25 21:02 ET
BioCryst Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-25 00:00 ET
BioCryst Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-24 07:06 ET
BioCryst Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-24 07:06 ET
BioCryst Pharmaceuticals reported for 2024 q4
SEC form 8
2025-01-10 00:00 ET
BioCryst Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-10 00:00 ET
BioCryst Pharmaceuticals published news for 2024 q4
SEC form 10
2024-11-05 17:19 ET
BioCryst Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-04 07:06 ET
BioCryst Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-04 07:06 ET
BioCryst Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-06 16:04 ET
BioCryst Pharmaceuticals published news for 2024 q2
SEC form 10
2024-08-06 00:00 ET
BioCryst Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-05 07:05 ET
BioCryst Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-05 07:05 ET
BioCryst Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-07 16:02 ET
BioCryst Pharmaceuticals published news for 2024 q1
SEC form 10
2024-05-07 00:00 ET
BioCryst Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-06 07:03 ET
BioCryst Pharmaceuticals reported for 2024 q1
SEC form 8
2024-05-06 07:03 ET
BioCryst Pharmaceuticals published news for 2024 q1
SEC form 10
2024-02-27 16:07 ET
BioCryst Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-27 00:00 ET
BioCryst Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-26 07:05 ET
BioCryst Pharmaceuticals reported for 2023 q4
SEC form 8
2024-02-26 07:05 ET
BioCryst Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
BioCryst Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
BioCryst Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-08 00:00 ET
BioCryst Pharmaceuticals published news for 2023 q3
SEC form 8
2023-11-02 07:05 ET
BioCryst Pharmaceuticals reported for 2023 q3
SEC form 6
2023-08-03 07:04 ET
BioCryst Pharmaceuticals reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
BioCryst Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-11 07:00 ET
BioCryst Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-14 07:02 ET
BioCryst Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
BioCryst Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
BioCryst Pharmaceuticals published news for 2023 q1
SEC form 10
2023-02-27 00:00 ET
BioCryst Pharmaceuticals reported for 2022 q4
SEC form 8
2023-02-21 00:00 ET
BioCryst Pharmaceuticals reported for 2022 q4
SEC form 8
2023-01-09 00:00 ET
BioCryst Pharmaceuticals published news for 2022 q4
SEC form 10
2022-11-04 00:00 ET
BioCryst Pharmaceuticals reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
BioCryst Pharmaceuticals reported for 2022 q3
SEC form 10
2022-08-05 00:00 ET
BioCryst Pharmaceuticals reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
BioCryst Pharmaceuticals reported for 2022 q2
SEC form 10
2022-05-09 00:00 ET
BioCryst Pharmaceuticals reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
BioCryst Pharmaceuticals reported for 2022 q1
SEC form 10
2022-02-28 00:00 ET
BioCryst Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
BioCryst Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
BioCryst Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-04 00:00 ET
BioCryst Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
BioCryst Pharmaceuticals published news for 2021 q3
SEC form 10
2021-08-09 00:00 ET
BioCryst Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
BioCryst Pharmaceuticals published news for 2021 q2
SEC form 10
2021-05-07 00:00 ET
BioCryst Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
BioCryst Pharmaceuticals published news for 2021 q1